The Biospecimen Extraction Resource (BER) is a centralized laboratory for standardized, high-quality, reasonably-priced DMA and RNA extraction from various sources. The BER performs PCR-based analysis of these nucleic acids including pyrosequencing for genotyping of single nucleotide polymorphisms and for detection of CpG island methylation. In addition, the BER consults with non-laboratory-based investigators to help them accomplish their laboratory-based goals related to the facility. The BER is located in the newlyconstructed Basic Science Research Building (BSRB). The BER uses state-of-the-art instrumentation including the Autopure LS automated DMA extraction machine and the PSQ pyrosequencer. The BER has an 8-member oversight committee. A website provides information about services, guidelines for preparing samples for DMA extraction, and other procedures performed by the facility, as well as forms to be completed when requesting service. In the current grant period, the BER was used by 35 different investigators from 17 programs with 98% of usage coming from investigators having peer-reviewed funding. Most of the DMA extractions are from human peripheral blood leukocytes or saliva. An increase of over 400% has been seen over the past year compared to those extracted in 2002. The source of funds for the proposed operating budget of the BER for year 33 (July 1, 2008-June 30, 2009) is 14% from TexGen, 53% from user fees, and 34% from the CCSG. Future plans include continued expansion to large projects such as TexGen, the """"""""LBJ Patient History Database-Serum/DNA Bank"""""""" and the """"""""Repository of Tissue and Blood on Patients in the Cancer Prevention Center.""""""""

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-37
Application #
8379480
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
37
Fiscal Year
2012
Total Cost
$75,668
Indirect Cost
$26,144
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Le, Phuong M; Andreeff, Michael; Battula, Venkata Lokesh (2018) Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica :
Huang, Shengjian; Jiang, Changying; Zhang, Hui et al. (2018) The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma. Blood Cancer J 8:33
Hwang, Jessica P; Ahmed, Sairah; Ariza-Heredia, Ella J et al. (2018) Low Rate of Cervical Cancer Screening among Women with Hematologic Malignancies after Stem Cell Transplant. Biol Blood Marrow Transplant 24:1094-1098
He, Jing; Huo, Lei; Ma, Junsheng et al. (2018) Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. Am J Clin Pathol 149:253-261
Schembre, Susan M; Liao, Yue; O'Connor, Sydney G et al. (2018) Mobile Ecological Momentary Diet Assessment Methods for Behavioral Research: Systematic Review. JMIR Mhealth Uhealth 6:e11170
Abbas, Hussein A; Bui, Ngoc Hoang Bao; Rajapakshe, Kimal et al. (2018) Distinct TP63 Isoform-Driven Transcriptional Signatures Predict Tumor Progression and Clinical Outcomes. Cancer Res 78:451-462
Zhu, Lele; Xie, Xiaoping; Zhang, Lingyun et al. (2018) TBK-binding protein 1 regulates IL-15-induced autophagy and NKT cell survival. Nat Commun 9:2812
Viswanathan, Chitra; Faria, Silvana; Devine, Catherine et al. (2018) [18F]-2-Fluoro-2-Deoxy-D-glucose-PET Assessment of Cervical Cancer. PET Clin 13:165-177
Debnam, James M; Chi, Tzehping L; Ketonen, Leena et al. (2018) Superiority of Multidetector Computed Tomography With 3-Dimensional Volume Rendering Over Plain Radiography in the Assessment of Spinal Surgical Instrumentation Complications in Patients With Cancer. J Comput Assist Tomogr :
Patel, V K; Lamothe, B; Ayres, M L et al. (2018) Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia 32:920-930

Showing the most recent 10 out of 12418 publications